These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 25850293

  • 1. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
    Nasedkina TV, Gromyko OE, Emel'ianova MA, Ignatova EO, Kazubskaia TP, Portnoĭ SM, Zasedatelev AS, Liubchenko LN.
    Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
    [Abstract] [Full Text] [Related]

  • 2. [Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips].
    Fedorova OE, Liubchenko LN, Paiadini IuG, Kazubskaia TP, Amosenko FA, Gar'kavtseva RF, Zasedatelev AS, Nasedkina TV.
    Mol Biol (Mosk); 2007; 41(1):37-42. PubMed ID: 17380889
    [Abstract] [Full Text] [Related]

  • 3. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Sokolenko AP, Sokolova TN, Ni VI, Preobrazhenskaya EV, Iyevleva AG, Aleksakhina SN, Romanko AA, Bessonov AA, Gorodnova TV, Anisimova EI, Savonevich EL, Bizin IV, Stepanov IA, Krivorotko PV, Berlev IV, Belyaev AM, Togo AV, Imyanitov EN.
    Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
    [Abstract] [Full Text] [Related]

  • 4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.
    Breast Cancer Res; 2011 Feb 28; 13(1):R20. PubMed ID: 21356067
    [Abstract] [Full Text] [Related]

  • 5. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP, Bogdanova N, Kluzniak W, Preobrazhenskaya EV, Kuligina ES, Iyevleva AG, Aleksakhina SN, Mitiushkina NV, Gorodnova TV, Bessonov AA, Togo AV, Lubiński J, Cybulski C, Jakubowska A, Dörk T, Imyanitov EN.
    Breast Cancer Res Treat; 2014 Jun 28; 145(2):553-62. PubMed ID: 24800916
    [Abstract] [Full Text] [Related]

  • 6. Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population.
    Grzybowska E, Siemińska M, Zientek H, Kalinowska E, Michalska J, Utracka-Hutka B, Rogozińska-Szczepka J, Kaźmierczak-Maciejewska M.
    Acta Biochim Pol; 2002 Jun 28; 49(2):351-6. PubMed ID: 12362976
    [Abstract] [Full Text] [Related]

  • 7. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M, Milly M, Zavodna K, Weismanova E, Gregorova J, Mlkva I, Ilencikova D, Kausitz J, Bartosova Z.
    Breast Cancer Res Treat; 2011 Feb 28; 126(1):119-30. PubMed ID: 21203900
    [Abstract] [Full Text] [Related]

  • 8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 28; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 9. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.
    Suspitsin EN, Sherina NY, Ponomariova DN, Sokolenko AP, Iyevleva AG, Gorodnova TV, Zaitseva OA, Yatsuk OS, Togo AV, Tkachenko NN, Shiyanov GA, Lobeiko OS, Krylova NY, Matsko DE, Maximov SY, Urmancheyeva AF, Porhanova NV, Imyanitov EN.
    Hered Cancer Clin Pract; 2009 Feb 25; 7(1):5. PubMed ID: 19338682
    [Abstract] [Full Text] [Related]

  • 10. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
    Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, Karlan BY, Friedman E, Kaufman B.
    Oncogene; 2010 Jan 07; 29(1):26-33. PubMed ID: 19802015
    [Abstract] [Full Text] [Related]

  • 11. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N, Kotar K, Foulkes WD.
    BMC Med Genet; 2003 Aug 11; 4():7. PubMed ID: 12911837
    [Abstract] [Full Text] [Related]

  • 12. Genetic Analysis of Multiple Primary Malignant Tumors in Women with Breast and Ovarian Cancer.
    Savkova A, Gulyaeva L, Gerasimov A, Krasil'nikov S.
    Int J Mol Sci; 2023 Apr 04; 24(7):. PubMed ID: 37047678
    [Abstract] [Full Text] [Related]

  • 13. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Fan Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu Y, Xie Y.
    Breast Cancer Res Treat; 2018 May 04; 169(1):59-67. PubMed ID: 29356917
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT.
    Rybchenko LA, Poluben LO, Bychkova GM, Stephanovych GV, Klymenko SV.
    Probl Radiac Med Radiobiol; 2019 Dec 04; 24():455-464. PubMed ID: 31841487
    [Abstract] [Full Text] [Related]

  • 16. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U, Cecener G, Tunca B, Tasdelen I.
    Cancer Invest; 2006 Dec 04; 24(5):484-91. PubMed ID: 16939956
    [Abstract] [Full Text] [Related]

  • 17. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.
    Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NY, Iyevleva AG, Chekmariova EV, Buslov KG, Shilov ES, Togo AV, Bit-Sava EM, Voskresenskiy DA, Chagunava OL, Devilee P, Cornelisse C, Semiglazov VF, Imyanitov EN.
    Fam Cancer; 2007 Dec 04; 6(3):281-6. PubMed ID: 17333477
    [Abstract] [Full Text] [Related]

  • 18. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
    Skasko E, Kluska A, Niwińska A, Kwiatkowska E, Bałabas A, Piatkowska M, Dabrowska M, Nowakowska D, Pieńkowski T.
    Onkologie; 2009 Apr 04; 32(4):182-8. PubMed ID: 19372713
    [Abstract] [Full Text] [Related]

  • 19. BRCA1 and BRCA2 mutations in a South American population.
    Jara L, Ampuero S, Santibáñez E, Seccia L, Rodríguez J, Bustamante M, Martínez V, Catenaccio A, Lay-Son G, Blanco R, Reyes JM.
    Cancer Genet Cytogenet; 2006 Apr 01; 166(1):36-45. PubMed ID: 16616110
    [Abstract] [Full Text] [Related]

  • 20. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
    Krivokuca A, Dobricic J, Brankovic-Magic M.
    J BUON; 2013 Apr 01; 18(3):594-600. PubMed ID: 24065469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.